Regeneron Pharmaceuticals Q4 Profit Decreases, But Beats Estimates

Regeneron Pharmaceuticals (REGN) announced earnings for fourth quarter that decreased from the same period last year but beat the Street estimates.

The company's bottom line came in at $917.7 million, or $8.06 per share. This compares with $1.159 billion, or $10.19 per share, last year.

Excluding items, Regeneron Pharmaceuticals reported adjusted earnings of $1.389 billion or $12.07 per share for the period.

Analysts on average had expected the company to earn $11.19 per share. Analysts' estimates typically exclude special items.

The company's revenue for the period rose 10.3% to $3.789 billion from $3.434 billion last year.

Regeneron Pharmaceuticals earnings at a glance (GAAP) :

-Earnings: $917.7 Mln. vs. $1.159 Bln. last year.
-EPS: $8.06 vs. $10.19 last year.
-Revenue: $3.789 Bln vs. $3.434 Bln last year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com